Minority enrollment on clinical trials enhances scientific rigor but requires structural changes and commitment
Dr Matt Boente shares this article from Gynecologic Oncology-online:
University of Washington School of Medicine, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology
A commitment to representative and equitable enrollment of marginalized populations in clinical trials is a shared value of all who are dedicated to high quality clinical research and aware of the role of health and healthcare in a just society. The known benefits of trial participation, including improved survival, are outcomes for which all communities should have equal access. Efforts to advance meaningful science are hindered by a limited understanding of social-environmental-biological interactions that are often best studied among marginalized communities where structural and environmental risks are more pronounced than in other communities.